23 May 2013
Keywords: repligen, rg1068, fails, autism, trial, usa-based, synthetic
Article | 05 January 2004
USA-based Repligen's RG1068, a synthetic human secretin, has failed to meet its primary goals in a Phase III trial for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2003
© 2013 thepharmaletter.com